224 reports of this reaction
1.9% of all LORLATINIB reports
#8 most reported adverse reaction
OEDEMA is the #8 most commonly reported adverse reaction for LORLATINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 224 FDA adverse event reports linking LORLATINIB to OEDEMA. This represents approximately 1.9% of all 11,506 adverse event reports for this drug.
Patients taking LORLATINIB who experience oedema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OEDEMA is a less commonly reported adverse event for LORLATINIB, but still significant enough to appear in the safety profile.
In addition to oedema, the following adverse reactions have been reported for LORLATINIB:
The following drugs have also been linked to oedema in FDA adverse event reports:
OEDEMA has been reported as an adverse event in 224 FDA reports for LORLATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OEDEMA accounts for approximately 1.9% of all adverse event reports for LORLATINIB, making it a notable side effect.
If you experience oedema while taking LORLATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.